|
18 Jun 2019 |
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
|
|
17 Jun 2019 |
BeiGene Regains Full Global Rights to Its Investigational Anti-PD-1 Antibody Tislelizumab
|
|
17 Jun 2019 |
TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress
|
|
17 Jun 2019 |
Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38
|
|
17 Jun 2019 |
BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors
|
|
17 Jun 2019 |
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
|
|
15 Jun 2019 |
Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
|
|
15 Jun 2019 |
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
|
|
15 Jun 2019 |
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
|
|
15 Jun 2019 |
Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
|
|
15 Jun 2019 |
Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
|
|
14 Jun 2019 |
Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
|
|
14 Jun 2019 |
FDA Approves Amgen And Allergan's KANJINTITM (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
|
|
14 Jun 2019 |
UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients
|
|
13 Jun 2019 |
Update on Etigilimab (TIGIT) Partnership
|
|
13 Jun 2019 |
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
|
|
13 Jun 2019 |
Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab
|
|
13 Jun 2019 |
First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma
|
|
13 Jun 2019 |
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
|
|
12 Jun 2019 |
BioInvent publishes first clinical data from BI-1206 Phase l/lla trials
|
|
12 Jun 2019 |
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure
|
|
12 Jun 2019 |
New Subcutaneous Formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) Shows Positive Results for the Treatment of Rheumatoid Arthritis (RA) In Data Presented at the Annual European Congress of Rheumatology (EULAR 2019)
|
|
12 Jun 2019 |
FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
|
|
11 Jun 2019 |
New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance
|
|
11 Jun 2019 |
FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
|
